...
首页> 外文期刊>Bone marrow transplantation >Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
【24h】

Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

机译:异体造血条件同种异体造血细胞移植后第7天,肿瘤坏死因子受体1升高,急性移植物抗宿主病。

获取原文
获取原文并翻译 | 示例

摘要

Acute GVHD has remained a significant cause of nonrelapse mortality after allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning. The role of TNF-alpha in the biology of acute GVHD after nonmyeloablative conditioning has not been studied thus far. Here, we measured TNF receptor 1 (TNFR1) as a surrogate marker for TNF-alpha in 106 patients before the start of the conditioning regimen (baseline) and 7 days after allogeneic HCT with nonmyeloablative conditioning. The nonmyeloablative regimen consisted of 2 Gy TBI alone (n=15), 2 Gy TBI plus fludarabine 90 mg/m2 (n=73), or 4 Gy TBI plus fludarabine 90 mg/m2 (n=18). TNFR1 levels increased significantly from baseline to day 7 after nonmyeloablative HCT (P<0.0001). Patients conditioned with 4 Gy TBI had higher TNFR1 day 7/baseline ratio than those conditioned with 2 Gy TBI (median 1.65 versus 1.25; P=0.01). In a multivariate Cox model, high TNFR1 day7/baseline ratio was associated with grades II-IV (HR=2.2, P=0.01) and grades III-IV (HR=2.9, P=0.007) acute GVHD, but had no impact on overall survival (P=0.8). In summary, our data suggest that nonmyeloablative conditioning induces the generation of TNF-alpha, and that the magnitude of TNF-alpha generation depends on the conditioning intensity (2 Gy versus 4 Gy TBI). Further, assessment of TNFR1 levels before and on day 7 after nonmyeloablative HCT provided useful information on subsequent risk of experiencing acute GVHD.
机译:急性GVHD仍然是采用非清髓条件的同种异体造血细胞移植(HCT)后非复发死亡率的重要原因。到目前为止,尚未研究过非清髓性调理后TNF-α在急性GVHD生物学中的作用。在这里,我们在开始接受调理方案(基线)之前和同种异体HCT进行非清髓性调理后7天,对106例患者中的TNF受体替代指标TNF受体1(TNFR1)进行了测量。非清髓方案由单独的2 Gy TBI(n = 15),2 Gy TBI加氟达拉滨90 mg / m2(n = 73)或4 Gy TBI加氟达拉滨90 mg / m2(n = 18)组成。非清髓性HCT后,从基线到第7天,TNFR1水平显着增加(P <0.0001)。 4 Gy TBI组患者的TNFR1第7天/基线比率高于2 Gy TBI组患者(中位数1.65对1.25; P = 0.01)。在多变量Cox模型中,高TNFR1第7天/基线比率与II-IV级(HR = 2.2,P = 0.01)和III-IV级(HR = 2.9,P = 0.007)急性GVHD相关,但对总生存期(P = 0.8)。总而言之,我们的数据表明非清髓性调理可诱导TNF-α的生成,而TNF-α的生成量取决于条件强度(2 Gy对4 Gy TBI)。此外,评估非清髓性HCT之前和之后第7天的TNFR1水平提供了有关随后发生急性GVHD风险的有用信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号